全文获取类型
收费全文 | 34630篇 |
免费 | 2399篇 |
国内免费 | 1432篇 |
专业分类
耳鼻咽喉 | 197篇 |
儿科学 | 262篇 |
妇产科学 | 54篇 |
基础医学 | 1841篇 |
口腔科学 | 57篇 |
临床医学 | 4738篇 |
内科学 | 13477篇 |
皮肤病学 | 59篇 |
神经病学 | 389篇 |
特种医学 | 1621篇 |
外科学 | 1637篇 |
综合类 | 7575篇 |
现状与发展 | 1篇 |
预防医学 | 926篇 |
眼科学 | 41篇 |
药学 | 3785篇 |
26篇 | |
中国医学 | 1711篇 |
肿瘤学 | 64篇 |
出版年
2024年 | 44篇 |
2023年 | 394篇 |
2022年 | 659篇 |
2021年 | 1224篇 |
2020年 | 1153篇 |
2019年 | 979篇 |
2018年 | 948篇 |
2017年 | 834篇 |
2016年 | 905篇 |
2015年 | 970篇 |
2014年 | 2049篇 |
2013年 | 2250篇 |
2012年 | 1702篇 |
2011年 | 1994篇 |
2010年 | 1689篇 |
2009年 | 1573篇 |
2008年 | 1704篇 |
2007年 | 1827篇 |
2006年 | 1760篇 |
2005年 | 1499篇 |
2004年 | 1307篇 |
2003年 | 1191篇 |
2002年 | 1031篇 |
2001年 | 1104篇 |
2000年 | 911篇 |
1999年 | 829篇 |
1998年 | 736篇 |
1997年 | 687篇 |
1996年 | 552篇 |
1995年 | 490篇 |
1994年 | 469篇 |
1993年 | 371篇 |
1992年 | 311篇 |
1991年 | 302篇 |
1990年 | 249篇 |
1989年 | 202篇 |
1988年 | 205篇 |
1987年 | 191篇 |
1986年 | 157篇 |
1985年 | 200篇 |
1984年 | 173篇 |
1983年 | 104篇 |
1982年 | 116篇 |
1981年 | 93篇 |
1980年 | 71篇 |
1979年 | 60篇 |
1978年 | 50篇 |
1977年 | 43篇 |
1976年 | 35篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
21.
Ewelina Kazimierczyk Andrzej Eljaszewicz Paula Zembko Ewa Tarasiuk Malgorzata Rusak Agnieszka Kulczynska-Przybik Marta Lukaszewicz-Zajac Karol Kaminski Barbara Mroczko Maciej Szmitkowski Milena Dabrowska Bozena Sobkowicz Marcin Moniuszko Agnieszka Tycinska 《Pharmacological reports : PR》2019,71(1):73-81
Background
Acute myocardial infarction (AMI) causes irreversible myocardial damage and release of inflammatory mediators, including cytokines, chemokines and miRNAs. We aimed to investigate changes in the levels of cytokines (IL-6, TNF-α and IL-10), miRNAs profiles (miR-146 and miR-155) and distribution of different monocyte subsets (CD14++CD16-, CD14++CD16+, CD14+CD16++) in the acute and post-healing phases of AMI.Methods
In eighteen consecutive AMI patients (mean age 56.78?±?12.4 years, mean left ventricle ejection fraction – LVEF: 41.9?±?9.8%), treated invasively, monocyte subsets frequencies were evaluated (flow cytometry), cytokine concentrations were analyzed (ELISA) as well as plasma miRNAs were isolated twice – on admission and after 19.2?±?5.9 weeks of follow-up. Measurements were also performed among healthy volunteers.Results
AMI patients presented significantly decreased frequencies of classical cells in comparison to healthy controls (median 71.22% [IQR: 64.4–79.04] vs. 84.35% [IQR: 81.2–86.7], p?=?0.001) and higher percent of both intermediate and non-classical cells, yet without statistical significance (median 6.54% [IQR: 5.14–16.64] vs. 5.87% [IQR: 4.48–8.6], p?=?0.37 and median 5.99% [IQR: 3.39–11.5] vs. 5.26% [IQR: 3.62–6.2], p?=?0.42, respectively). In AMI patients both, analyzed plasma miRNA concentrations were higher than in healthy subjects (miR-146: median 5.48 [IQR: 2.4–11.27] vs. 1.84 [IQR: 0.87–2.53], p?=?0.003; miR-155: median 25.35 [IQR: 8.17–43.15] vs. 8.4 [IQR: 0.08–16.9], p?=?0.027, respectively), and returned back to the values found in the control group in follow-up. miR-155/miR-146 ratio correlated with the frequencies of classical monocytes (r=0.6, p?=?0.01) and miR-155 correlated positively with the concentration of inflammatory cytokines ? IL-6 and TNF-α.Conclusions
These results may suggest cooperation of both pro-inflammatory and anti-inflammatory signals in AMI in order to promote appropriate healing of the infarcted myocardium. 相似文献22.
23.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
24.
25.
26.
目的探讨急性心肌梗死(AMI)患者急诊经皮冠状动脉介入治疗(PCI)术后血清三碘甲状腺原氨酸(T3)与心肌再灌注的关系。方法采用化学发光法检测205例AMI患者PCI术后血清T3水平,根据T3水平将患者分为A、B、C、D4组,记录并比较4组患者术后冠状动脉TIMI血流分级、心肌呈色分级(MBG)。结果A组(重度低T3组)TIMI3级比例低于B、C、D组,差异有统计学意义(P<0.01);MBG3级比例低于B、C、D组,差异有统计学意义(P<0.01)。女性患者T3水平(1.00±0.05)nmol/L、TIMI3级比例(32/46,69.6%)、MBG3级比例(24/46,52.2%)均低于男性患者,后者分别为(1.19±0.02)nmol/L、(143/159,89.9%)、(110/159,69.2%),差异均有统计学意义(P<0.05或0.01)。结论女性AMI患者心肌再灌注水平较男性患者低。AMI患者T3水平与PCI术后冠状动脉再灌注相关,监测T3可以间接反映病情的严重程度。 相似文献
27.
何慧 《中国继续医学教育》2020,(4):160-162
目的总结并归纳护理干预对急性心肌梗死患者负性情绪的影响。方法本文挑选100例医院急性心肌梗死患者(2017年2月—2018年2月)为对象。按建档时间分组,对照组50例患者(常规护理),分析组50例患者(加用人文性护理)。比较两组对疾病的了解程度及护理前后焦虑、抑郁等负性情绪的评分,随访1年,比较两组复发率。结果护理后分析组对疾病了解程度高于对照组(P<0.05);护理前分析组焦虑、抑郁评分同对照组无显著差异(P>0.05),提示可比;护理后,分析组焦虑、抑郁评分低于对照组(P<0.05);护理后分析组1年内复发率(8.00%)低于对照组(24.00%)(P<0.05)。结论在急性心肌梗死患者的护理中,人文性护理干预可显著改善患者负性情绪,改善患者预后,且可有效降低患者复发率。 相似文献
28.
《Archives of Cardiovascular Diseases》2019,112(5):343-353
Central illustration: geographic distribution of the 49 centres participating in the FRENSHOCK registry (35 academic hospitals, 10 general hospitals and four private clinics). Inclusion per centre varied from 1 to 72 patients. 相似文献
29.
30.